Outcome of sub-massive pulmonary thromboemboli in patients who received thrombolytic and or non-thrombolytic therapy

• Main Authors: Hasan Allah Sadeghi, Mona Heidarali, Fusieh Faraji, Behshid Ghadrdoost, Maryam Shojaeifard
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2016-01-01
• Series: Research in Cardiovascular Medicine
• Subjects: Thrombolytic Therapy; Heparin Therapy; Massive Pulmonary Thromboembolism; Sub-Massive Pulmonary Emboli
• Online Access: http://www.rcvmonline.com/article.asp?issn=2251-9572;year=2016;volume=5;issue=3;spage=2;epage=2;aulast=Sadeghi;type=0

Background: Thrombolytic therapy in patients with sub-massive pulmonaryembolism (SMPTE) needs further assessment. Objectives: The current study aimed to assess a potential benefit of thrombolytic and non-thrombolytic therapy in patients with SMPTE. Patients and Methods: One hundred-nineteen patients were enrolled with SMPTE from 2006 to 2010 in the tertiary care center of Rajaie medical and research center. The patients who had pulmonary thromboemboli (PTE) and received thrombolytic plus heparin therapy and or non-thrombolytic (unfractionated heparin alone) were evaluated for hemodynamic changes (blood pressure, pulse rate, pulmonary artery systolic pressure, right ventricular failure and right ventricle enlargement), before and after 48 hours of treatment. The mortality rate was also assessed. Results: Forty-five percent of the patients with SMPTE received thrombolytic therapy (streptokinase) and 55% of SMPTE patients received non-thrombolytic therapy (unfractionated heparin). Pulse rate, pulmonary arterial pressure and tricuspid regurgitation gradient in patients receiving thrombolytic therapy reduced significantly (P = 0.001, P = 0.01 and P= 0.001, respectively). There was no significant difference before and after treatment regarding systolic blood pressure (P = 0.4), diastolic blood pressure (DBP) (P = 0.5), systolic arterial pressure (SPAP) (P= 0.1), Right ventricular (RV) function (P = 0.1) and RVsize (P = 0.1). In patients who received a non-thrombolytic therapy, there were no significant differences between the groups regarding SBP(P= 0.2), DBP( P= 0. 4) and PR (P=0.1), SPAP (P = 0.6), TRG (P = 0.4), RV function (P= 0.4) and RVsize (P = 0.2) before and after treatment. There were no significant differences between the groups according to mortality rate. Conclusions: Thrombolytic therapy lead to earlier relief of hemodynamic condition in comparison to non-thrombolytic therapy but no changes were observed in mortality rate.